Fredrik Bergh ThorÃ©n

List of Publications by Year
in descending order

60 papers	1,595 citations	257450 24 h-index	315739 38 g-index
64 all docs	64 docs citations	64 times ranked	2138 citing authors

#	Article	IF	Citations
1	Human NK Cells Induce Neutrophil Apoptosis via an NKp46- and Fas-Dependent Mechanism. Journal of Immunology, 2012, 188, 1668-1674.	0.8	96
2	A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals. Journal of Leukocyte Biology, 2004, 76, 1180-1186.	3.3	81
3	NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species. British Journal of Haematology, 2006, 132, 91-98.	2.5	80
4	Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis. Blood, 2012, 119, 5832-5837.	1.4	75
5	Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Blood Reviews, 2013, 27, 209-216.	5.7	71
6	Cutting Edge: Antioxidative Properties of Myeloid Dendritic Cells: Protection of T Cells and NK Cells from Oxygen Radical-Induced Inactivation and Apoptosis. Journal of Immunology, 2007, 179, 21-25.	0.8	56
7	Changes in Activation States of Murine Polymorphonuclear Leukocytes (PMN) during Inflammation: a Comparison of Bone Marrow and Peritoneal Exudate PMN. Vaccine Journal, 2006, 13, 575-583.	3.1	55
8	The CD16â"/CD56bright Subset of NK Cells Is Resistant to Oxidant-Induced Cell Death. Journal of Immunology, 2007, 179, 781-785.	0.8	55
9	A Proinflammatory Peptide from Herpes Simplex Virus Type 2 Glycoprotein G Affects Neutrophil, Monocyte, and NK Cell Functions. Journal of Immunology, 2005, 174, 2235-2241.	0.8	53
10	Oxygen Radicals Induce Poly(ADP-Ribose) Polymerase-Dependent Cell Death in Cytotoxic Lymphocytes. Journal of Immunology, 2006, 176, 7301-7307.	0.8	51
11	The HLA-B â"21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood, 2019, 133, 1479-1488.	1.4	50
12	Postâ€consolidation Immunotherapy with Histamine Dihydrochloride and Interleukinâ€2 in AML. Scandinavian Journal of Immunology, 2009, 70, 194-205.	2.7	48
13	TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses. Journal of Immunology, 2015, 195, 1121-1128.	0.8	48
14	Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 1473-1484.	4.2	45
15	Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Expert Review of Hematology, 2010, 3, 381-391.	2.2	44
16	Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. Haematologica, 2012, 97, 1904-1908.	3.5	44
17	Histamine Promotes the Development of Monocyte-Derived Dendritic Cells and Reduces Tumor Growth by Targeting the Myeloid NADPH Oxidase. Journal of Immunology, 2015, 194, 5014-5021.	0.8	38
18	Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells. Oncotarget, 2016, 7, 32046-32053.	1.8	37

#	Article	IF	Citations
19	Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. Acta OncolÃ³gica, 2006, 45, 389-399.	1.8	35
20	NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. Oncotarget, 2015, 6, 42569-42574.	1.8	35
21	Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. OncoImmunology, 2016, 5, e1041701.	4.6	34
22	Role of the ERK Pathway for Oxidant-Induced Parthanatos in Human Lymphocytes. PLoS ONE, 2014, 9, e89646.	2.5	31
23	The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands. Frontiers in Immunology, 2017, 8, 510.	4.8	29
24	miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 2020, 8, 119.	3.7	26
25	Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2. Frontiers in Oncology, 2018, 8, 218.	2.8	25
26	Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia. Expert Opinion on Biological Therapy, 2009, 9, 1217-1223.	3.1	23
27	Activation of cytotoxic lymphocytes by interferon-Î±: role of oxygen radical-producing mononuclear phagocytes. Journal of Leukocyte Biology, 2004, 76, 1207-1213.	3.3	21
28	NOX2-dependent immunosuppression in chronic myelomonocytic leukemia. Journal of Leukocyte Biology, 2017, 102, 459-466.	3.3	21
29	Redox Remodeling by Dendritic Cells Protects Antigen-Specific T Cells against Oxidative Stress. Journal of Immunology, 2011, 187, 6243-6248.	0.8	20
30	Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. Cancer Immunology, Immunotherapy, 2013, 62, 1547-1551.	4.2	20
31	Analyzing Cell Death Events in Cultured Leukocytes. Methods in Molecular Biology, 2012, 844, 65-86.	0.9	20
32	A simple skin blister technique for the study of in vivo transmigration of human leukocytes. Journal of Immunological Methods, 2013, 393, 8-17.	1.4	19
33	Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia. Journal of Leukocyte Biology, 2017, 102, 467-474.	3.3	17
34	Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. Leukemia, 2017, 31, 2552-2559.	7.2	16
35	Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML. Leukemia and Lymphoma, 2019, 60, 2771-2778.	1.3	15
36	Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes. Journal of Leukocyte Biology, 2013, 93, 155-160.	3.3	14

#	Article	IF	Citations
37	Antitumor properties of histamine in vivo. Nature Medicine, 2011, 17, 537-537.	30.7	13
38	Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype. Human Vaccines and Immunotherapeutics, 2020, 16, 109-111.	3.3	13
39	Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. Oncotarget, 2016, 7, 7586-7596.	1.8	13
40	Histamine Dihydrochloride Maintains Cytotoxic Effector T Lymphocyte Function and Viability under Conditions of Oxidative Stress.. Blood, 2007, 110, 2309-2309.	1.4	13
41	Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha â€" can tumor immune escape after immunotherapy accelerate disease progression?. OncoImmunology, 2016, 5, e1091147.	4.6	12
42	Downregulation of HLA Class I Renders Inflammatory Neutrophils More Susceptible to NK Cell-Induced Apoptosis. Frontiers in Immunology, 2019, 10, 2444.	4.8	12
43	CD20 antibodies induce production and release of reactive oxygen species by neutrophils. Blood, 2014, 123, 4001-4002.	1.4	11
44	Impact of IL-1Î² and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance. OncoImmunology, 2021, 10, 1944538.	4.6	11
45	Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species. Cancer Immunology Research, 2020, 8, 1532-1541.	3.4	10
46	Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells. Neoplasia, 2018, 20, 25-31.	5.3	9
47	Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia. Cancer Immunology Research, 2018, 6, 1110-1119.	3.4	8
48	The anionic amphiphile SDS is an antagonist for the human neutrophil formyl peptide receptor 1. Biochemical Pharmacology, 2010, 80, 389-395.	4.4	7
49	Immunotherapy with histamine dihydrochloride and lowâ€dose interleukinâ€2 favors sustained lymphocyte recovery in acute myeloid leukemia. European Journal of Haematology, 2015, 94, 279-280.	2.2	5
50	Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapseâ€preventive immunotherapy in acute myeloid leukaemia. British Journal of Haematology, 2020, 188, e49-e53.	2.5	4
51	Adjuvant interferon: extended follow-up times needed?. Lancet Oncology, The, 2011, 12, 419.	10.7	2
52	Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia. Frontiers in Immunology, 2021, 12, 796072.	4.8	2
53	Abstract 2545: Histamine dihydrochloride and interleukin-2 for relapse prevention in AML: Initial results of the Re:MISSION phase IV trial. Cancer Research, 2014, 74, 2545-2545.	0.9	1
54	P-06 Long term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: a controlled, randomized multicentre trial. Melanoma Research, 2007, 17, A19.	1.2	0

#	Article	IF	Citations
55	Abstract 5414: Malignant monocytic AML cells trigger apoptosis in anti-leukemic lymphocytes: Role of NADPH oxidase gp91phoxexpression and PARP-1 activity. , 2012, , .		0
56	Abstract B66: Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent cell death in natural killer cells.. , 2013, , .		0
57	Reactive Oxygen Species Produced By Myeloid Cells Block CD20-Antibody Dependent NK Cell-Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells. Blood, 2014, 124, 3638-3638.	1.4	0
58	Natural Killer Cell Expression of Natural Cytotoxicity Receptors Determines Relapse Risk in Elderly Patients with Acute Myeloid Leukemia Receiving Immunotherapy with Histamine Dihydrochloride and Interleukin-2. Blood, 2014, 124, 3680-3680.	1.4	0
59	Abstract CT116: Dynamics of cytotoxic T-cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. , 2016, , .		0
60	Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia. Blood, 2019, 134, 1318-1318.	1.4	0